This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Endocyte Inks Deal For Prostate Cancer Candidate, Shares Up
by Zacks Equity Research
Endocyte (ECYT) acquired an exclusive worldwide license to develop and commercialize ABX GmbH's phase III-ready prostate cancer candidate 177Lu-PSMA-617.
Mallinckrodt, NeuroproteXeon Team Up for Inhalation Therapy
by Zacks Equity Research
Mallinckrodt plc (MNK) entered into a licensing agreement with NeuroproteXeon for the development and commercialization of the latter's investigational, pharmaceutical-grade xenon gas for inhalation therapy.
Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA
by Zacks Equity Research
Allergan (AGN) announced that the FDA has accepted the application for the label expansion of Avycaz to include a new indication and study data.
Seattle Genetics' Adcetris Gets Breakthrough Therapy Status
by Zacks Equity Research
Seattle Genetics' (SGEN) lymphoma drug, Adcetris has been granted Breakthrough Therapy Designation by the FDA for treating patients with advanced classical Hodgkin lymphoma with no prior treatments.
3 Top-Ranked Big Biotech Stocks to Buy Now
by Zacks Equity Research
With biotech stocks on a tear, here we have picked three of the biggest biotech companies which look well poised for growth and can be added to one's portfolio
FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that the FDA has accepted the company's sBLA and granted Priority Review for breast cancer drug regimen Perjeta
Novo Nordisk's Fiasp Gets FDA Nod for Diabetes in Adults
by Zacks Equity Research
Novo Nordisk's (NVO) fast-acting mealtime insulin aspart, Fiasp, has been approved by the FDA for the treatment of adults with diabetes.
Lilly (LLY) Makes Leadership Changes to Executive Positions
by Zacks Equity Research
Eli Lilly and Company (LLY) makes some executive appointments for various departments.
Prothena's Psoriasis Candidate Disappoints in Phase I Study
by Zacks Equity Research
Prothena Corporation plc (PRTA) announced disappointing results from a phase Ib study of pipeline candidate, PRX003 in psoriasis patients.
Mallinckrodt (MNK) Closes InfaCare Pharmaceutical Buyout
by Zacks Equity Research
Mallinckrodt (MNK) acquires privately-held InfaCare Pharmaceutical Corporation to diversify portfolio.
Infinity/ Bristol-Myers Adds TNBC Patients to Clinical Deal
by Zacks Equity Research
Infinity (INFI) expanded its existing clinical collaboration with Bristol-Myers Squibb for evaluating IPI-549 in combination with Opdivo to include patients with triple negative breast cancer.
Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer
by Zacks Equity Research
AbbVie (ABBV) and Bristol-Myers Squibb entered into a deal to evaluate the combination of ABBV-399 and Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer.
The Medicines Co. Continues to Focus on Pipeline Development
by Zacks Equity Research
The Medicines Co.'s (MDCO) divestment of non-core assets should allow the company to focus on key assets and brings in a non-dilutive source of funds as well.
Bayer (BAYRY) Focuses on Pipeline Development & Acquisitions
by Zacks Equity Research
Bayer (BAYRY) remains focused on developing its pipeline and acquisitions in order to boost its portfolio.
Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up
by Zacks Equity Research
Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.
How is the Age-Related Macular Degeneration Space Faring Now?
by Zacks Equity Research
The Age-Related Macular Degeneration (AMD) space has been in the spotlight of late due to a number of developments.
ProQR's Genetic Disorder Candidate Gets Orphan Drug Status
by Zacks Equity Research
ProQR Therapeutics (PRQR) announced that its investigational dystrophic epidermolysis bullosa candidate, QR-313, was granted orphan drug designation by the FDA.
Teva/Nuvelution to Speed Up Development of Austedo in US
by Zacks Equity Research
Teva Pharma (TEVA) and Nuvelution inked a deal to accelerate the development of Austedo (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome.
Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia
by Zacks Equity Research
Alkermes (ALKS) announced encouraging results from a phase IV study of ARISTADA for the treatment of schizophrenia.
Pluristem's Ischemia Candidate Gets Fast Track Designation
by Zacks Equity Research
Pluristem Therapeutics' (PSTI) phase III study of PLX-PAD cells in patients with critical limb ischemia granted Fast Track designation by the FDA.
Zacks.com featured highlights include include Hasbro, Regeneron Pharmaceuticals, Applied Materials, Vantiv, and CBRE Group
by Zacks Equity Research
Zacks.com featured highlights include include Hasbro, Regeneron Pharmaceuticals, Applied Materials, Vantiv, and CBRE Group
Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU
by Zacks Equity Research
Glaxo's (GSK) single inhaler triple therapy for the treatment of COPD in patients who are already being treated with a ICS/LAMA combination received a positive opinion from the CHMP in the EU.
5 Top Stocks with Impressive Sales Growth Worth Betting On
by Zacks Equity Research
Steady sales growth is the key to survival for any business. Also, it is an important tool for making investment decisions.
Pfizer Xtandi Succeeds in Early Stage Prostate Cancer Study
by Zacks Equity Research
Pfizer's (PFE) prostate cancer drug Xtandi met the primary endpoint in a late-stage study, which can expand the label of the drug to include early-stage patients.
Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study
by Zacks Equity Research
Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.